Genitourinary Cancer
Commentary
Discontinuing immunotherapy: Is the infusion bag half empty or half full?
Clinical trials of immunotherapy or chemoimmunotherapy have generally terminated treatment in nonprogressing patients after 2 years.
Conference Coverage
How AI is, or will soon be, relevant in radiation oncology
Radiation oncologists at ASTRO 2022 discuss practical applications of AI, and new research findings.
From the Journals
Chronic stress, especially race related, may hasten cancer death
High allostatic load was associated with an 80% increased risk of cancer death among all study participants.
From the Journals
Third COVID booster benefits cancer patients
For the first time, researchers have quantified the benefits of boosters for COVID-19 in cancer patients.
Feature
$38,398 for a single shot of a very old cancer drug
The first issue is unrelenting price increases on old drugs that have remained branded as manufacturers find ways to extend patents for decades...
From the Journals
Is early-onset cancer an emerging global epidemic?
“This paper ... brings to light the importance of correctable lifestyle habits that may slow the rise of early onset cancers.”
Diminutio
Cancer as a full contact sport
The complexity of cancer care has long necessitated a team approach to planning cancer treatment.
From the Journals
Despite benefits, extended-interval pembro uptake remains low
It’s possible that low uptake could stem from clinicians’ doubts about switching to an extended-interval dose, given that the FDA’s approval was...
Conference Coverage
High BMI linked to better survival for cancer patients treated with ICI, but for men only
The reasons behind the findings and implications for treatment are unknown, as is whether it applies to patients with specific cancers.
Conference Coverage
A farewell to arms? Drug approvals based on single-arm trials can be flawed
Objective responses, not time-dependent survival outcomes, should be endpoints for single-arm trials, with results only used for conditional...
Conference Coverage
Time to cancer diagnoses in U.S. averages 5 months
Diagnosis time varied significantly across tumor types, as well as within the same tumor type.